Hot Stocks in the News – June 18, 2025

June 18, 2025

DENVER, Colo., Jun 18, 2025 (247marketnews.com)- Venu (NYSE:VENU) is making waves after announcing the groundbreaking of a $350 million amphitheater in McKinney, Texas—touted as the largest fully seated, multi-seasonal amphitheater ever constructed. In an interview on the Schwab Network, Founder and CEO J.W. Roth shared that Venu is currently developing $1.2 billion worth of entertainment venues, with a $3 billion buildout pipeline targeted over the next 3–4 years. The company leverages an effective financing model combining public-private partnerships (PPP), fractional ownership, and sale-leasebacks. Roth highlighted Venu’s financing model: “35 to 45% of our financing comes from municipality partnerships… another 35–45% from fractional ownership… the rest usually in the form of a sale leaseback.”

Please click here to view the interview.

Venu also filed an 8-K confirming the close of a $10.25 million equity investment with an institutional investor at a premium, with convertible preferred shares priced effectively at $15 per share.

KWESST (NASDAQ:KWE) received a prototype order for its next-gen Battlefield Laser Detection System (BLDS) for a major North American armored vehicle program. The BLDS tech, which detects laser-guided threats like LTDs and LRFs, is designed for soldier-worn or vehicle-mounted deployment. BLDS represents a “leap ahead” in survivability and tactical awareness. Prototypes are now being finalized and will undergo operational testing this year, with fully networked versions expected by fall 2025.

Aptevo Therapeutics (NASDAQ:APVO) reported 85% remission rates in unfit AML patients from its ongoing Phase 1b/2 RAINIER trial, which evaluates mipletamig, a CD123 x CD3 bispecific antibody. The mipletamig + venetoclax/azacitidine combination outperformed historical benchmarks and demonstrated no CRS or dose-limiting toxicities. Remarkably, one patient advanced to stem cell transplant—a rare outcome in this high-risk group. CEO Marvin White emphasized mipletamig’s differentiated CD3 engineering strategy, positioning it as a potential new frontline standard in AML treatment.

Sharps Technology (NASDAQ:STSS) is scaling operations with the second shipment under its $50 million SoloGard syringe agreement, alongside major manufacturing upgrades. Enhancements include advanced injection molding, 10x energy-efficient equipment, and optimized cleanroom infrastructure. Sharps is executing a $400,000 order as part of a five-year deal to supply up to 500 million FDA- and WHO-approved SoloGard smart syringes.

Arqit Quantum (NASDAQ:ARQQ) was named an inaugural member of the Oracle Defense Ecosystem (NYSE:ORCL) during the Oracle Defense Tech Summit in Austin, TX. The initiative focuses on reshaping defense innovation and infrastructure modernization. Arqit’s quantum-safe encryption solutions are gaining attention for their ability to secure mission-critical systems against future cyber threats. Its Senior Director spotlighted the company’s role in protecting data in a post-quantum world, reinforcing Arqit’s strategic value in national security tech stacks.

Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (VENU, KWE, APVO, STSS, ARQQ, ORCL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.